The recent study by Perez-Pietro et al. (2025), published in the Journal of Experimental Orthopaedics, is based on data from the Catalan Arthroplasty Register and covers a ten-year period (2007–2017). The study focused on implant survival following primary knee arthroplasty. For the first time, PALACOS® bone cements were compared in a blinded setup with other individual products and brands, taking into account different viscosities and the presence or absence of included antibiotics (PALACOS® with and without gentamicin).
The use of PALACOS® bone cements – with and without antibiotics – yielded favourable results in terms of revision rates. The most significant difference was observed in the segment of antibiotic-loaded bone cements. The revision rate for PALACOS® R+G states 1.8%, compared to 3.9% for the corresponding competitive products.
For the first time, the study also presented data on the medium-viscous bone cement PALACOS® MV+G from Heraeus Medical in knee arthroplasty, which also showed convincing results. Here, the revision rate states 1.1% compared to 3.9% for other antibiotic-loaded bone cements over the ten-year period.
The statistical analysis revealed no significantly increased risk of revision for any of the PALACOS® products examined.
The study’s findings highlight the importance of evidence-based decision-making in knee arthroplasty and confirm PALACOS® bone cements as a reliable option for long-term implant survival.
The published study is available open access here:
Heraeus Medical LLC770 Township Line RoadYardley 19067United States